Clinical trials: Neoadjuvant Radiotherapy
Breast Cancer
SIGNAL During a COVID-19 Pandemic
The standard treatment for early stage, estrogen-receptor positive breast cancer is lumpectomy and sentinel lymph node biopsy followed by 16-25 treatments of adjuvant whole-breast radiation therapy plus or minus hormone therapy.
- Trial name
- NCT05037019
- Testing
- Radiation therapy
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
ESCC
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study
This prospective, single-arm phase II study will evaluate the efficacy and safety of lymphatic-drainage-sparing short-course radiotherapy combined with camrelizumab and nab-paclitaxel/carboplatin as neoadjuvant treatment for…
- Trial name
- NeoSCRTIC-01 (NCT07808853)
- Testing
- Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma
Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT
The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) could be delineated according to the post-NACT tumor position and receive radical radiation dose, while the tumor disappear after NACT could be…
- Trial name
- NCT03283293
- Testing
- Target Volume Delineation after NACT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Glioblastoma
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2).
- Trial name
- NCT06551909
- Testing
- Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer
Proton Radiation for Resectable Carcinoma of the Pancreas
The purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy and surgery has on you and your pancreatic cancer.
- Trial name
- PC02 (NCT00763516)
- Testing
- Proton radiation and chemotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Florida
Neoadjuvant Immunotherapy, NSCLC
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which…
- Conditions
- Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy
- Trial name
- NCT07231575
- Testing
- SBRT, Immunotherapy, antiangiogenesis therapy
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Bladder (Urothelial, Transitional Cell) Cancer
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC.
- Trial name
- NCT07053722
- Testing
- NA-TMT
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Soft Tissue Sarcoma
High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
This is a single-arm open-label phase Ib/II clinical study assessing the efficacy of concurrent high dose ascorbate in combination with radiotherapy in patients with locally advanced, resectable, high grade sarcomas.
- Trial name
- NCT03508726
- Testing
- Ascorbate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mohammed Milhem
Pancreatic Cancer
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with…
- Trial name
- NCT01458717
- Testing
- Neoadjuvant chemoradiation, Upfront surgery
- Where
- 5 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- Seoul National University Hospital
Soft Tissue Sarcoma
Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
The primary objective of this study was to evaluate the safety and efficacy of paamprilimab combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma.
- Trial name
- NCT05718778
- Testing
- Piamprimab (AK105)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University
Rectal Adenocarcinoma
Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma
The purpose of this study is to assess the effects, both good and bad, of adding very low dose fractionated radiation therapy (LDFRT) to the pelvis, with FOLFOX chemotherapy prior to surgery.
- Trial name
- GCC 1314 (NCT02319304)
- Testing
- FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated radiation therapy (LDFRT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Maryland, Baltimore
Cutaneous Squamous Cell Carcinoma (CSCC)
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
The goal of this clinical trial is to evaluate if short-course radiation therapy (SCRT) can effectively treat high-risk cutaneous squamous cell carcinoma (cSCC) and if active surveillance is a safe alternative to radiation for…
- Trial name
- MOHSAHRTSS (NCT06998342)
- Testing
- Short course radiation, Active Surveillance
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using…
- Trial name
- pCOLA (NCT06986486)
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bladder Cancer
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
STAR-EV will evaluate the combination of enfortumab vedotin plus radiotherapy (RT) as neoadjuvant treatment for bladder cancer prior to radical cystectomy surgery.
- Trial name
- STAR-EV (NCT06394570)
- Testing
- Enfortumab vedotin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Texas Southwestern Medical Center
Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free…
- Conditions
- Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response
- Trial name
- THUNDER2 (NCT04815694)
- Testing
- RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Cancer
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
- Trial name
- XERT (NCT00689702)
- Testing
- cetuximab, capecitabine
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Triple Negative Breast Cancer
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
This phase II randomized trial is for patients with clinical stage II-III, ER and PR <10%, HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT is planned and pre-operative RT is deemed…
- Trial name
- PANDoRA (NCT03872505)
- Testing
- Durvalumab, Radiation Therapy, Carboplatin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- SACTION 2501 (NCT07309952)
- Testing
- Sintilimab, Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yang Hong